Amy Schumer shared her positive experience being on Mounjaro, a prescription drug that's approved to treat Type 2 diabetes ...

Mounjaro (Tirzepatide), a groundbreaking GLP-1 receptor agonist targeting GIP receptors, is now available in India for ...

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an ...

Month after claiming Ozempic left her 'bedridden', Amy Schumer revealed she's been using a different diabetes medication as a ...

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...

Amy Schumer recently took to her Instagram handle to share her experience with Midi Health. The 43-year-old actress-comedian ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

The makers of Wegovy and Zepbound are cutting prices to make the medications more affordable for people without insurance.

Jefferies isn’t sweating Eli Lilly’s slightly slimmer projections for its weight-loss drug Orfo, maintaining a spicy $1,020 ...